186 related articles for article (PubMed ID: 35546431)
1. CMV specific T cell immune response in hepatitis C negative kidney transplant recipients receiving transplant from hepatitis C viremic donors and hepatitis C aviremic donors.
Azhar A; Tsujita M; Talwar M; Balaraman V; Bhalla A; Eason JD; Nouer SS; Sumida K; Remport A; Hall IE; Griffin R; Rofaiel G; Molnar MZ
Ren Fail; 2022 Dec; 44(1):831-841. PubMed ID: 35546431
[TBL] [Abstract][Full Text] [Related]
2. Kidney transplant from hepatitis C viremic donors into aviremic recipients and risk for post-transplant BK and cytomegalovirus infection.
Daloul R; Schnelle K; Von Stein L; Logan A; Singh P; Yenebere P; Pesavento T; Washburn K
Transpl Infect Dis; 2022 Aug; 24(4):e13887. PubMed ID: 35752929
[TBL] [Abstract][Full Text] [Related]
3. The incidence of cytomegalovirus infection after deceased-donor kidney transplantation from hepatitis-C antibody positive donors to hepatitis-C antibody negative recipients.
Yazawa M; Fülöp T; Cseprekal O; Talwar M; Balaraman V; Bhalla A; Azhar A; Kovesdy CP; Eason JD; Molnar MZ
Ren Fail; 2020 Nov; 42(1):1083-1092. PubMed ID: 33100098
[TBL] [Abstract][Full Text] [Related]
4. [Monitoring of cytomegalovirus-specific CD4+ and CD8+ T cell responses by cytokine flow cytometry in renal transplant recipients].
Kılınçkaya Doğan H; Mutlu E; Köksoy S; Yılmaz VT; Koçak H; Çolak D; Mutlu D; Günseren F; Dinçkan A; Aliosmanoğlu İ; Süleymanlar G; Gültekin M
Mikrobiyol Bul; 2016 Apr; 50(2):224-35. PubMed ID: 27175495
[TBL] [Abstract][Full Text] [Related]
5. Short-term outcomes of deceased donor renal transplants of HCV uninfected recipients from HCV seropositive nonviremic donors and viremic donors in the era of direct-acting antivirals.
La Hoz RM; Sandıkçı B; Ariyamuthu VK; Tanriover B
Am J Transplant; 2019 Nov; 19(11):3058-3070. PubMed ID: 31207073
[TBL] [Abstract][Full Text] [Related]
6. Successful early sofosbuvir-based antiviral treatment after transplantation of kidneys from HCV-viremic donors into HCV-negative recipients.
Friebus-Kardash J; Gäckler A; Kribben A; Witzke O; Wedemeyer H; Treckmann J; Herzer K; Eisenberger U
Transpl Infect Dis; 2019 Oct; 21(5):e13146. PubMed ID: 31306562
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis C Virus NAT-Positive Solid Organ Allografts Transplanted Into Hepatitis C Virus-Negative Recipients: A Real-World Experience.
Kapila N; Menon KVN; Al-Khalloufi K; Vanatta JM; Murgas C; Reino D; Ebaid S; Shaw JJ; Agrawal N; Rhazouani S; Navas V; Sheffield C; Rahman AU; Castillo M; Lindenmeyer CC; Miller C; Quintini C; Zervos XB
Hepatology; 2020 Jul; 72(1):32-41. PubMed ID: 31659775
[TBL] [Abstract][Full Text] [Related]
8. Prospective Multicenter Study of Early Antiviral Therapy in Liver and Kidney Transplant Recipients of HCV-Viremic Donors.
Terrault NA; Burton J; Ghobrial M; Verna E; Bayer J; Klein C; Victor D; Mohan S; Trotter J; Dodge J; Niemann CU; Rubin RA
Hepatology; 2021 Jun; 73(6):2110-2123. PubMed ID: 32926749
[TBL] [Abstract][Full Text] [Related]
9. Increasing Utilization and Excellent Initial Outcomes Following Liver Transplant of Hepatitis C Virus (HCV)-Viremic Donors Into HCV-Negative Recipients: Outcomes Following Liver Transplant of HCV-Viremic Donors.
Cotter TG; Paul S; Sandıkçı B; Couri T; Bodzin AS; Little EC; Sundaram V; Charlton M
Hepatology; 2019 Jun; 69(6):2381-2395. PubMed ID: 30706517
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis C viremic lung transplantation to aviremic recipients: Comprehensive outcomes and post-transplant viremia.
Khan S; Mazumder R; Wang X; Wang Y; Sims OT; Budev M; Carey W
Clin Transplant; 2024 May; 38(5):e15325. PubMed ID: 38716770
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic utility of monitoring cytomegalovirus-specific immunity by QuantiFERON-cytomegalovirus assay in kidney transplant recipients.
Deborska-Materkowska D; Perkowska-Ptasinska A; Sadowska A; Gozdowska J; Ciszek M; Serwanska-Swietek M; Domagala P; Miszewska-Szyszkowska D; Sitarek E; Jozwik A; Kwiatkowski A; Durlik M
BMC Infect Dis; 2018 Apr; 18(1):179. PubMed ID: 29661141
[TBL] [Abstract][Full Text] [Related]
12. Center-level trends in utilization of HCV-exposed donors for HCV-uninfected kidney and liver transplant recipients in the United States.
Bowring MG; Shaffer AA; Massie AB; Cameron A; Desai N; Sulkowski M; Garonzik-Wang J; Segev DL
Am J Transplant; 2019 Aug; 19(8):2329-2341. PubMed ID: 30861279
[TBL] [Abstract][Full Text] [Related]
13. Prevention of viral transmission during lung transplantation with hepatitis C-viraemic donors: an open-label, single-centre, pilot trial.
Cypel M; Feld JJ; Galasso M; Pinto Ribeiro RV; Marks N; Kuczynski M; Kumar D; Bahinskaya I; Bagnato VS; Kurachi C; Slutsky AS; Yeung JC; Donahoe L; de Perrot M; Yasufuku K; Pierre A; Binnie M; Chaparro C; Martinu T; Chen M; Tikkanen J; Chow CW; Sidhu A; Waddell TK; Keshavjee S; Singer LG; Humar A
Lancet Respir Med; 2020 Feb; 8(2):192-201. PubMed ID: 31606437
[TBL] [Abstract][Full Text] [Related]
14. Trends in Discard of Kidneys from Hepatitis C Viremic Donors in the United States.
Chang SH; Merzkani M; Lentine KL; Wang M; Axelrod DA; Anwar S; Schnitzler MA; Wellen J; Chapman WC; Alhamad T
Clin J Am Soc Nephrol; 2021 Feb; 16(2):251-261. PubMed ID: 33451990
[TBL] [Abstract][Full Text] [Related]
15. National trends and outcomes of heart-kidney transplantation using hepatitis C positive donors.
Diaz-Castrillon CE; Huckaby LV; Witer L; Pope NH; Katz MR; Baliga PK; Kilic A
Clin Transplant; 2022 Apr; 36(4):e14581. PubMed ID: 34974630
[TBL] [Abstract][Full Text] [Related]
16. Regular monitoring of cytomegalovirus-specific cell-mediated immunity in intermediate-risk kidney transplant recipients: predictive value of the immediate post-transplant assessment.
Fernández-Ruiz M; Giménez E; Vinuesa V; Ruiz-Merlo T; Parra P; Amat P; Montejo M; Paez-Vega A; Cantisán S; Torre-Cisneros J; Fortún J; Andrés A; San Juan R; López-Medrano F; Navarro D; Aguado JM;
Clin Microbiol Infect; 2019 Mar; 25(3):381.e1-381.e10. PubMed ID: 29803844
[TBL] [Abstract][Full Text] [Related]
17. Development of CMV-specific cytotoxic T cells (CMV-Tc) in pediatric renal transplant recipients with CMV viremia.
Pizzo H; Shin B; Garrison J; Huang E; Malekzadeh M; Jordan SC; Puliyanda D; Toyoda M
Pediatr Transplant; 2021 Dec; 25(8):e14119. PubMed ID: 34390094
[TBL] [Abstract][Full Text] [Related]
18. Access to direct-acting antivirals for hepatitis C-negative transplant recipients receiving organs from hepatitis C-viremic donors.
Bova S; Cameron A; Durand C; Katzianer J; LeGrand M; Boyer L; Glorioso J; Toman LP
Am J Health Syst Pharm; 2022 Jan; 79(3):173-178. PubMed ID: 33987658
[TBL] [Abstract][Full Text] [Related]
19. Factors associated with hepatitis C antibody seroconversion after transplantation of kidneys from hepatitis C infected donors to hepatitis C naïve recipients.
Agbim U; Cseprekal O; Yazawa M; Talwar M; Balaraman V; Bhalla A; Podila PSB; Maliakkal B; Nair S; Eason JD; Molnar MZ
Ren Fail; 2020 Nov; 42(1):767-775. PubMed ID: 32729359
[TBL] [Abstract][Full Text] [Related]
20. Kidney transplant from HCV viremic donors to HCV-negative recipients and risk for de novo donor specific antibodies and acute rejection.
Daloul R; Sureshkumar K; Schnelle K; Von Stein L; Logan A; Pesavento T
Clin Transplant; 2023 Feb; 37(2):e14895. PubMed ID: 36580971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
